In Vitro and in Vivo Angiogenesis in PC12 Pheochromocytoma Cells is Mediated by Vascular Endothelial Growth Factor

Summary

Angiogenesis, the formation of new blood vessels from existing vascular endothelium, is essential for tumor growth. Vascular endothelial growth factor (VEGF) is an endotheliumspecific mitogen and regulator of angiogenesis. Angiogenesis has been associated to the malignant phenotype of pheochromocytomas and is readily observed in experimental pheochromocytomas. Although VEGF gene expression has already been demonstrated in the rat PC12 cell line, the detailed mechanisms of action are not known. We have, therefore, studied angiogenesis in the rat PC12 pheochromocytoma cell line in vitro and in vivo. VEGF gene expression and accumulation of VEGF protein in cytoplasm and conditioned medium of PC12 cells was found. Conditioned medium from PC12 cells significantly increased proliferation of VEGF-dependent endothelial cells from human umbilical veins, and this effect reversed upon addition of a neutralizing anti-VEGF antibody. Dexamethasone and nerve growth factor (NGF) increased VEGF mRNA expression and accumulation of VEGF protein of PC12 subclones with established metastatic activity in vivo. PC12 cells xenotransplanted to nude mice had marked VEGF expression and induced host angiogenesis, confirmed by the presence of CD34-positive endothelial cells in the experimental PC12 tumors. When NGF-primed PC12 cells were immobilized in Matrigel supplemented with rising concentrations of the growth factor and xenotransplanted, increasing NGF resulted in tumors with smaller areas of necrosis and increased vital tumor volume.

These results suggest that VEGF is a mediator of angiogenesis in the PC12 pheochromocytoma cell line, and that dexamethasone and NGF affect VEGF expression. Our data further suggest that NGF may contribute to angiogenesis in experimental pheochromocytoma.

Pheochromocytoma - Angiogenesis - Growth factor - VEGF

References

• 1 Barth P J, Weingärtner K, Köhler H H, Bittinger A. Assessment of the vascularization in prostatic carcinoma: a morphometric investigation.  Hum Pathol . 1996;  27 1306-1310
• 2 Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S, De Rosa G, Salvatore G, Fusco A, Persico M G, Viglietto G. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and anti-sense vascular endothelial growth factor gene.  Oncogene . 1999;  18 4860-4869
• 3 Berman M E, Xie Y, Muller W A. Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and β2 integrin activation.  J Immunol . 1996;  156 1515-1524
• 4 Claffey K P, Wilkison W O, Spiegelman B M. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways.  J Biol Chem . 1992;  267 16 317-16 322
• 5 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor.  Endocrine Rev . 1997;  18 4-25
• 6 Folkman J, Hochberg M. Self-regulation of growth in three dimensions.  J Exp Med. 1973;  138 745-753
• 7 Gess B, Sandner P, Kurtz A. Differential effects of kinase inhibitors on erythropoietin and vascular endothelial growth factor gene expression in rat hepatocytes.  Pflugers Arch. 1996;  432 426-432
• 8 Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis.  Virchows Arch. 1995;  426 479-486
• 9 Hofbauer L C, Gori F, Riggs B L, Lacey D L, Dunstan C R, Spelsberg T C, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.  Endocrinology. 1999;  140 4382-4389
• 10 Kleinman H K, McGarvey M L, Liotta L A, Robey P G, Tryggvason K, Martin G R. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma.  Biochemistry. 1982;  21 6188-6193
• 11 Liu Q, Djuricin G, Staren E D, Gattuso P, Gould V E, Shen J, Saclarides T, Rubin D B, Prinz R A. Tumor angiogenesis in pheochromocytomas and paragangliomas.  Surgery. 1996;  120 938-942 , discussion 942-943
• 12 Passaniti A, Taylor R M, Pili R, Guo Y, Long P V, Haney J A, Pauly R R, Grant D S, Martin G R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.  Lab Invest. 1992;  67 519-528
• 13 Sandner P, Gess B, Wolf K, Kurtz A. Divergent regulation of vascular endothelial growth factor and of erythropoietin gene expression in vivo.  Pflugers Arch. 1996;  431 905-912
• 14 Sato K, Miyakawa M, Onoda N, Demura H, Yamashita T, Miura M, Kasajima T, Yamazaki K, Obara T. Increased concentration of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules.  J Clin Endocrinol Metab. 1997;  82 1968-1973
• 15 Senger D R, Claffey K P, Benes J E, Perruzzi C A, Sergiou A P, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins.  Proc Natl Acad Sci USA. 1997;  94 13 612-13 617
• 16 Sheehy A M, Phung Y T, Riemer R K, Black S M. Growth factor induction of nitric oxide synthase in rat pheochromocytoma cells.  Brain Res Mol Brain Res. 1997;  52 71-77
• 17 Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.  Nature. 1992;  359 843-845
• 18 Zielke A, Bresalier R S, Siperstein A E, Clark O H, Rothmund M, Duh Q Y. A unique allogenic model of metastatic pheochromocytoma: PC12 rat pheochromocytoma xenografts to nude mice and establishment of metastases-derived PC12 variants.  Clin Exp Metastasis. 1998;  16 341-352
• 19 Zielke A, Wong M G, Siperstein A E, Clark O H, Rothmund M, Duh Q Y. Antiproliferative effect of suramin on primary cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells.  J Surg Oncol. 1997;  66 11-18